Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan

An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1–10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of microbiology, immunology and infection immunology and infection, 2020-06, Vol.53 (3), p.488-492
Hauptverfasser:	Cheng, Chien-Yu, Lee, Yu-Lin, Chen, Cheng-Pin, Lin, Yi-Chun, Liu, Chun-Eng, Liao, Chia-Hung, Cheng, Shu-Hsing
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Betacoronavirus - drug effects Chloroquine - therapeutic use Coronavirus Infections - drug therapy Coronavirus Infections - pathology COVID-19 Drug Combinations Female Humans Lopinavir - therapeutic use Lopinavir/ritonavir (LPV/r) Male Middle Aged Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - pathology Ribavirin - therapeutic use Ritonavir - therapeutic use SARS CoV-2 Shedding Taiwan Virus Shedding - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An increase of Ct values was 0.9 per day in 2 cases of COVID-19 treated with lopinavir/ritonavir (LPV/r), an increase was 1.0 per day in 3 cases without LPV/r through illness day 1–10, indicating that LPV/r did not shorten the duration of SARS CoV-2 shedding.
ISSN:	1684-1182 1995-9133
DOI:	10.1016/j.jmii.2020.03.032